Literature DB >> 26490990

The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells.

Omer Faruk Karatas1, Ilknur Suer2, Betul Yuceturk2,3, Mehmet Yilmaz4, Yusif Hajiyev5, Chad J Creighton6, Michael Ittmann7,8, Mustafa Ozen9,10,11.   

Abstract

The cancer stem-like cells (CSLCs) are tumorigenic cells promoting initiation, progression, and spread of the tumor. Accumulating evidences suggested the presence of CSLCs in distinct tumors including laryngeal squamous cell carcinoma (LSCC). MicroRNAs have been proposed as significant regulators of carcinogenesis, and several of them have been demonstrated to have direct roles in survival of CSLCs. In this study, we aimed to explore the role of miR-145, which is downregulated in LSCC, on cancer stem cell potency of laryngeal cancer cells. We initially showed the downregulation of miR-145 expression in tumor tissue samples and in CD133-enriched CSLCs. Quantitative reverse-transcription PCR (qRT-PCR) analysis of miR-145-transfected Hep-2 cells demonstrated the inhibitory role of miR-145 on stem cell markers like SOX2, OCT4, KLF4, and ABCG2. We, then, investigated the stem cell features of miR-145-overexpressing Hep-2 cells by sphere formation assay, single-cell cloning assay, and aldehyde dehydrogenase (ALDH) assay, which all demonstrated the inhibition of stem cell potency upon miR-145 overexpression. Further qRT-PCR analysis demonstrated altered expression of epithelial to mesenchymal transition markers in miR-145-overexpressing Hep-2 cells. In conclusion, we demonstrated the regulatory role of miR-145 in stem cell characteristics of Hep-2 cells. Based on these results, we propose that miR-145 might carry crucial roles in LSCC tumorigenesis, prognosis, metastasis, chemoresistance, and recurrence through regulating stem cell properties of tumor cells.

Entities:  

Keywords:  Cancer stem-like cells; Hsa-miR-145; Laryngeal squamous cell carcinoma; Stem cell markers

Mesh:

Substances:

Year:  2015        PMID: 26490990     DOI: 10.1007/s13277-015-4219-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture.

Authors:  Sandra Papini; Denise Cecchetti; Daniela Campani; Wendy Fitzgerald; Jean Charles Grivel; Silvia Chen; Leonid Margolis; Roberto P Revoltella
Journal:  Stem Cells       Date:  2003       Impact factor: 6.277

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Role of miR-145 in human laryngeal squamous cell carcinoma.

Authors:  Omer Faruk Karatas; Betul Yuceturk; Ilknur Suer; Mehmet Yilmaz; Harun Cansiz; Mustafa Solak; Michael Ittmann; Mustafa Ozen
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

Review 5.  Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.

Authors:  Caterina Fanali; Donatella Lucchetti; Marisa Farina; Maddalena Corbi; Valerio Cufino; Achille Cittadini; Alessandro Sgambato
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 6.  Cancer stem cells.

Authors:  Zuoren Yu; Timothy G Pestell; Michael P Lisanti; Richard G Pestell
Journal:  Int J Biochem Cell Biol       Date:  2012-09-02       Impact factor: 5.085

7.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

Review 8.  The role of miRNAs in cancer: from pathogenesis to therapeutic implications.

Authors:  Mehmet Seven; Omer Faruk Karatas; Mehmet Bugrahan Duz; Mustafa Ozen
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404

Review 9.  Emerging role of microRNAs in cancer and cancer stem cells.

Authors:  Jin Hao; Sen Zhao; Yueling Zhang; Zhihe Zhao; Rui Ye; Jianing Wen; Juan Li
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

10.  Location and clonal analysis of stem cells and their differentiated progeny in the human ocular surface.

Authors:  G Pellegrini; O Golisano; P Paterna; A Lambiase; S Bonini; P Rama; M De Luca
Journal:  J Cell Biol       Date:  1999-05-17       Impact factor: 10.539

View more
  15 in total

1.  MiRNA-mRNA crosstalk in laryngeal squamous cell carcinoma based on the TCGA database.

Authors:  Guan-Jiang Huang; Meng-Si Luo; Guo-Ping Chen; Min-Yi Fu
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-13       Impact factor: 2.503

Review 2.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

3.  Dissecting the biological relationship between TCGA miRNA and mRNA sequencing data using MMiRNA-Viewer.

Authors:  Yongsheng Bai; Lizhong Ding; Steve Baker; Jenny M Bai; Ethan Rath; Feng Jiang; Jianghong Wu; Hui Jiang; Gary Stuart
Journal:  BMC Bioinformatics       Date:  2016-10-06       Impact factor: 3.169

4.  Analysis of gene expression profiling variations induced by hsa‑miR‑145‑5p‑overexpression in laryngeal squamous cell carcinoma cell line Tu‑177.

Authors:  Yongxia Ding; Yongyan Wu; Wei Gao; Chunming Zhang; Qinli Zhao; Huina Guo; Xukuan Qu; Shuxin Wen; Binquan Wang
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 2.952

5.  Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway.

Authors:  Qiang Fu; Pengruofeng Liu; Xiumei Sun; Shanshan Huang; Fengchan Han; Lili Zhang; Yannan Xu; Tingyan Liu
Journal:  Cancer Cell Int       Date:  2017-09-05       Impact factor: 5.722

6.  Identification and characterization of CD133+CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines.

Authors:  Jue Wang; Yongyan Wu; Wei Gao; Fei Li; Yunfeng Bo; Meixia Zhu; Rong Fu; Qingqing Liu; Shuxin Wen; Binquan Wang
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

7.  Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance.

Authors:  Zhennan Yuan; Cheng Xiu; Kaibin Song; Rong Pei; Susheng Miao; Xionghui Mao; Ji Sun; Shenshan Jia
Journal:  J Cell Mol Med       Date:  2018-07-04       Impact factor: 5.310

8.  Potential prognostic markers and significant lncRNA-mRNA co-expression pairs in laryngeal squamous cell carcinoma.

Authors:  Junguo Wang; Dingding Liu; Yajun Gu; Han Zhou; Hui Li; Xiaohui Shen; Xiaoyun Qian
Journal:  Open Life Sci       Date:  2021-06-02       Impact factor: 0.938

9.  A Meta-Analysis: Identification of Common Mir-145 Target Genes that have Similar Behavior in Different GEO Datasets.

Authors:  Elnaz Pashaei; Esra Guzel; Mete Emir Ozgurses; Goksun Demirel; Nizamettin Aydin; Mustafa Ozen
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

10.  Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1.

Authors:  Wei Gao; Chunming Zhang; Wenqi Li; Huizheng Li; Jiangwei Sang; Qinli Zhao; Yunfeng Bo; Hongjie Luo; Xiwang Zheng; Yan Lu; Yong Shi; Dongli Yang; Ruiping Zhang; Zhenyu Li; Jiajia Cui; Yuliang Zhang; Min Niu; Jun Li; Zhongqiang Wu; Huina Guo; Caixia Xiang; Juan Wang; Juan Hou; Lu Zhang; Rick F Thorne; Yongping Cui; Yongyan Wu; Shuxin Wen; Binquan Wang
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.